Skip to main content

Table 1 Correlation between KSR2 levels in 198 HCC patients and their clinicopathologic characteristics

From: KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma

Variate n KSR2 expression
Low High p value
Age     0.200
  < 53 103 47 56
  ≥ 53 95 52 43
Gender     1.000
 Male 170 85 85
 Female 28 14 14
HBsAg     0.852
 No 35 17 18
 Yes 163 82 81
Anti-HCV     0.902
 No 7 4 3
 Yes 191 95 96
Liver cirrhosis     0.817
 No 21 11 10
 Yes 177 88 89
AFP     0.769
  < 20 ng/mL 74 36 38
  ≥ 20 ng/mL 124 63 61
ALT     0.540
  ≤ 50 U/L 136 70 66  
  > 50 U/L 62 29 33  
GGT     1.000
  ≤ 60 U/L 112 56 56  
  > 60 U/L 86 43 43  
Number of tumors     0.182
 1 165 79 86
  > 1 33 20 13
Tumor size     0.032
  < 5 cm 111 63 48
  ≥ 5 cm 87 36 51
Tumor differentiation     0.752
 good /middle 142 70 72
 poor 56 29 27
Tumor capsule     0.670
 No 95 49 46
 Yes 103 50 53
Stage     0.641
 I 139 71 68
 II 59 28 31